Navigation Links
EPGL Technology Selected by Major Corporation for Development

IRVINE, Calif., Dec. 16, 2013 /PRNewswire/ -- EP Global Communications, Inc., (OTC Ticker EPGL) makes the following announcement:

In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products.

The Development Agreement was signed last week, being the week of December 8, 2013.

"This is the biggest development for our company in its history,"  said David T. Markus PhD.  "This is just the first of many possible Agreements to come for EPGL and its advanced technologies.  EPGL is a leader in BioMEMS technology and the companies we develop with will become leaders as well in this field for their particular products."

The two companies have signed a confidentiality agreement due to the sensitive and competitive nature of the technology.  Details of the first Development Agreement will remain confidential for now.  However, PwC as custodian for AJW Funds Board membership of EPGL has been apprised of the Agreement and its details.

EPGL currently has over 15 new advanced technologies and corporations in the medical device and consumer electronics fields have sought to enter relationship with the company.  Because of this development, EPGL intends to expand upon and focus on this business model going forward. 

EPGL Management and Team would like to wish all of our shareholders a Merry Christmas, Happy Hanukkah and Happy New Year.

About EP Global Communications, Inc.
EP Global Communications, Inc. is an advanced technology development company for both medical devices and consumer electronics.  EPGL also holds an FDA 510k cleared medical device called the MPD1. The MPD1 is a revolutionary new diagnostic and therapeutic tool for the muscular originated pain in the human body.

Safe Harbor Statement
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

SOURCE EP Global Communications, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First And Only Skincare To Use Plant And Human Adult Stem Cell Technology Launches
2. Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel
3. Lincor Upgrades Patient Engagement Technology, Launches New Product Portfolio
4. Frost & Sullivan Applauds Definiens Strong Technology Portfolio for the Effective Data Analysis of Histology Images
5. Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and Award Programs - Research Report on BD, Sanofi, GSK, Agilent Technologies, and Align Technology
6. The OR Company Acquires Rights to Baltimore-Based Start-Up Technology
7. Drug Solubility Technology: Spray Drying, Extrusion, and SCF
8. Orcasonix Unveils Innovative Ultrasound Technology Built on Cephasonics cQuest Family of Ultrasound Systems
9. Cincinnati Childrens Issued Patent Covering Individualized Medication Dosing Technology
10. Technology & Innovation Transforming Pharmaceutical Sales Training Programs
11. 3D Printing, the Disruptive Technology for World Manufacturing has a New Patent Granted to Renowned Inventor Donald Spector
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):